- Data to highlight latest long-term preclinical efficacy and durability data supporting PBGENE-DMD for the treatment of Duchenne Muscular Dystrophy - - On track to file an IND and/or CTA by the end ...
The AASLD late-breaking presentations will focus on the recent IMPACT Phase 2b readout of the 24-week data. In addition, Altimmune expects to announce 48-week data in Q4 2025. A copy of the ...
New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster session - ...
Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first ...
Both datasets were accepted for late-breaking poster presentations, highlighting the program's potential impact on innate immune checkpoint blockade. HCB101's progress reflects its distinct ...
Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data ...
Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results